Benzinga | Aug 2, 2021 08:49AM EDT

Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna

* Autolus Therapeutics plc (NASDAQ:AUTL) has granted Moderna Inc (NASDAQ:MRNA) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.

* Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments.

* In addition, Autolus would be entitled to receive royalties on net sales.

* Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.